HR 1794: Commissioner of Insurance; conduct a comprehensive review of prescription drug pricing and identify strategies to reduce the cost of prescription medications; urge

This resolution does not change Georgia law. Instead, it expresses the House's wish that the Commissioner of Insurance, who oversees Georgia's insurance market, conduct a comprehensive review of prescription drug pricing. The review would look at cost drivers throughout the pharmaceutical supply chain, including drug manufacturers, pharmacy benefit managers, and insurers, and would aim to identify strategies to reduce prescription drug costs for people in Georgia. The resolution notes that other states have used tools like all-payer claims data, advisory panels, and reporting requirements to study drug affordability, and suggests Georgia could take a similar approach. It calls for a report of findings and recommendations to be sent to the Governor, the President of the Senate, and the Speaker of the House, and directs the Clerk of the House to distribute copies to the Commissioner of Insurance, the public, and the press.

• Urges (but does not legally require) the Commissioner of Insurance to conduct a comprehensive review of prescription drug pricing in Georgia.
• Asks the review to identify strategies for reducing prescription medication costs for Georgia residents.
• Calls for a report on findings and recommendations to be submitted to the Governor, the Senate President, and the House Speaker.
• Directs the Clerk of the House to distribute copies of the resolution to the Commissioner of Insurance, the public, and the press.

The Commissioner of Insurance's office, which would be asked to lead the review; Georgia patients and families facing prescription drug costs; and stakeholders in the pharmaceutical supply chain such as drug manufacturers, pharmacy benefit managers, and insurers whose practices would be examined.

If the Commissioner acts on this request, Georgians could eventually see a public report explaining what drives high prescription drug costs and possible policy fixes. Because it is a resolution rather than a law, nothing is legally mandated and no new rules or funding are created.

• The resolution recites findings that rising drug prices burden patients, families, employers, and public health programs in Georgia.
• It notes that other states have used all-payer claims data, advisory panels, and reporting requirements to study drug affordability.
• The operative resolving clause urges the Commissioner of Insurance to conduct a comprehensive pricing review and identify cost-reduction strategies.
• A further resolving clause requires a report of findings and recommendations to go to the Governor, the Senate President, and the House Speaker.
• A final clause directs the Clerk of the House to distribute copies to the Commissioner of Insurance, the public, and the press.

1. 2026-03-23House Second Readers (Cámara de Representantes)
2. 2026-03-20House First Readers (Cámara de Representantes)
3. 2026-03-19House Hopper (Cámara de Representantes)

• Bryce Berry (D, HD-056)Patrocinador principal
• Tangie Herring (D, HD-145)
• Samuel Park (D, HD-107)
• Spencer Frye (D, HD-122)
• Carolyn Hugley (D, HD-141)
• Eric Gisler (D, HD-121)

• prescription drug prices
• health insurance
• pharmacy benefit managers
• consumer protection